In order to broaden its vaccine development pipeline, Takeda Pharmaceutical has agreed to acquire the Singaporean vaccine company Inviragen in a deal worth up to US$250 M, including US$35 M upfront. With the acquisition, Takeda will gain Inviragen’s lead asset DENVax™, a tetravalent recombinant viral vaccine for the prevention of dengue infection, one of four WHO future vaccine priorities. DENVax faces competition from Sanofi Pasteur’s dengue vaccine candidate, which also targets all four virus types but which fell short of expectations in a Phase IIb trial in which it reported efficacy of just 30%.